Qilu Pharmaceutical Gains Temporary FDA Approval to Import Cisplatin Amid US Shortage
Qilu Pharmaceutical, a China-based firm, has benefited from the effects of drug shortages in the...
Drug
CStone Pharmaceuticals and Blueprint Medicines’ Ayvakit Wins FDA Approval for ISM Treatment
Partners CStone Pharmaceuticals (HKG: 2616) and Blueprint Medicines have announced that the US FDA has...
Sirnaomics Initiates Phase I Clinical Trial for Anticoagulant Drug Candidate STP122G
Sirnaomics Ltd (HKG: 2257) has announced the first systemic dosing of a Phase I clinical...
CANbridge Pharmaceuticals’ Maralixibat Approved by NMPA for Alagille Syndrome
China-based rare disease specialist CANbridge Pharmaceuticals Inc., (HKG: 1228) has announced receiving market approval from...
Innovent Biologics Partners with Merck KGaA to Test KRAS Inhibitor Combo in NSCLC
China-based Innovent Biologics (HKG: 1801) has announced a clinical study and supply agreement with German...
Akeso Biopharma’s Ebronucimab NDA Accepted for Review by China’s NMPA
China-based Akeso Biopharma (HKG: 9926) has announced that the National Medical Products Administration (NMPA) has...
Jiangsu Hengrui Medicine’s SHR-1905 and SHR7280 Receive NMPA Clinical Trial Approvals
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced receiving clinical trial approvals from...
Brii Biosciences Initiates Phase I Study for BRII-297 in Australia
China’s Brii Biosciences (HKG: 2137) has announced the first patient dosing in a Phase I...
AIM Vaccine’s Omicron BA.5 mRNA Vaccine Shows 73.16% Efficacy in China Trial
China-based AIM Vaccine Co., Ltd (HKG: 6660) has revealed the protective efficacy of its Omicron...
Betta Pharmaceuticals’ Befotertinib Approved by China’s NMPA for EGFR-Mutated NSCLC
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced receiving market approval from the National...
Antengene’s Xpovio Combination Therapy Approved for Reimbursement in Australia for R/R MM
China-based biotech Antengene Corp., Ltd (HKG: 6996) has revealed that Australia’s Pharmaceutical Benefits Scheme (PBS)...
HighField Biopharmaceuticals Presents Promising HF1K16 Data at ASCO Annual Meeting
Hangzhou-based biotech HighField Biopharmaceuticals has revealed the publication of an abstract at this year’s American...
Luzhu Biotechnology’s Herpes Zoster Vaccine LZ901 Concludes Phase II Study
Beijing Luzhu Biotechnology Co., Ltd (HKG: 2480), a leading maker of human vaccines and therapeutic...
CMS Receives NMPA Approval for Tildrakizumab for Plaque Psoriasis Treatment
China Medical System Holdings (CMS; HKG: 0867) has announced receiving marketing approval from the National...
CSPC Pharmaceutical’s AlaMab Therapeutics Presents Positive ALMB-0168 Data at ASCO
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its subsidiary, AlaMab Therapeutics Inc.,...
Betta Pharmaceuticals Secures Exclusive Rights to C4 Therapeutics’ CFT8919 in Greater China
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced an exclusive licensing agreement with US...
BeiGene’s Brukinsa Receives Canadian Approval for Chronic Lymphocytic Leukemia
China-based BeiGene Ltd (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that its Bruton’s tyrosine...
Chia Tai Tianqing’s Biosimilar Rituximab Approved by China’s NMPA for Lymphoma Treatments
China-based Chia Tai Tianqing has announced receiving a market approval from the National Medical Products...
Jiangsu Hengrui Pharmaceuticals Secures NMPA Approvals for SHR-2106 and HRS-1893 Clinical Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has separately announced receiving clinical trial approvals...
AstraZeneca Launches Calquence in China for Mantle Cell Lymphoma Treatment
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has announced the official market launch of Calquence...